Patient group
Erwachsene und Jugendliche ab 12 Jahren mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine systemische Therapie infrage kommen
Added benefit not proven
Comparator
Dupilumab (ggf. in Kombination mit TCS und/oder TCI)
final resolution2024-06-06active
Arzneimittel-Richtlinie/Anlage XII: Lebrikizumab (Atopische Dermatitis, ≥ 12 Jahre)
Open official decision page ↗
G-BA source · retrieved 2026-08-05
Structured conclusion
Final result by patient group
1 source-verified result
Decision orientation
What the G-BA did
4 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
- Decision date
- 2024-06-06
- Effective
- 06.06.2024
- Action type
- final resolution
- Committee
- Arzneimittel
Case context
Listed normative targets
directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V
A listed target is not treated as a new directive version unless an official version source exists.
Official document package